Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
About This Grant
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.
Grant Summary
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS is a Health and Human Services Department grant providing funding that varies by award for healthcare org. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $0K
See notice
- 1Confirm your organization is eligible for Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS from Health and Human Services Department, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to Health and Human Services Department before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against Health and Human Services Department's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS: Frequently Asked Questions
Who is eligible for the Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS?
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS is offered by Health and Human Services Department and is generally open to healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS provide?
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS provides an amount that varies by award per award from Health and Human Services Department. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS deadline?
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, Health and Human Services Department, before you apply, and submit as early as possible because rolling programs can close once funds are committed.
How do you apply for the Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS?
To apply for Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from Health and Human Services Department.